C4 Therapeutics, Inc.
CCCC
$2.53
-$0.08-3.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.55% | 98.56% | 71.44% | 65.45% | 83.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.55% | 98.56% | 71.44% | 65.45% | 83.26% |
| Cost of Revenue | 11.99% | 3.58% | -6.01% | -8.01% | -11.95% |
| Gross Profit | -10.22% | 17.30% | 22.59% | 23.33% | 26.74% |
| SG&A Expenses | -1.41% | -0.62% | 0.10% | -0.55% | -1.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.24% | 2.44% | -4.40% | -6.04% | -9.20% |
| Operating Income | -6.15% | 12.09% | 15.72% | 16.44% | 19.45% |
| Income Before Tax | -4.56% | 17.35% | 19.84% | 21.43% | 23.78% |
| Income Tax Expenses | -89.77% | -89.77% | -89.77% | -72.38% | -- |
| Earnings from Continuing Operations | -3.44% | 18.08% | 20.51% | 21.81% | 22.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.44% | 18.08% | 20.51% | 21.81% | 22.87% |
| EBIT | -6.15% | 12.09% | 15.72% | 16.44% | 19.45% |
| EBITDA | -6.05% | 12.28% | 15.89% | 16.53% | 19.60% |
| EPS Basic | 16.71% | 37.95% | 43.20% | 38.03% | 33.45% |
| Normalized Basic EPS | 14.43% | 35.05% | 43.04% | 37.81% | 35.17% |
| EPS Diluted | 16.71% | 37.95% | 43.20% | 38.11% | 33.53% |
| Normalized Diluted EPS | 14.43% | 35.05% | 43.04% | 37.81% | 35.17% |
| Average Basic Shares Outstanding | 18.66% | 28.41% | 39.74% | 31.51% | 21.29% |
| Average Diluted Shares Outstanding | 18.66% | 28.41% | 39.74% | 31.51% | 21.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |